Knutsford-based Crawford secures Canadian exclusivity deal

Wound-care company Crawford Healthcare has signed a new deal with Canada-based Exciton Technologies to strengthen its place in the global healthcare market.

The agreement will see the rights for advanced materials developer Exciton’s silver oxysalt technology, designed for antimicrobial wound treatment, awarded to Crawford Healthcare.

While Crawford has been working with Exciton under licence for the last three years, the company moved to sign a global exclusivity agreement following what it called a “dramatic market response” to the use of the patented technology in the UK and US.

Crawford Healthcare’s CEO, Richard Anderson, said of the deal: “This exclusivity agreement strengthens our position as a new market leader with a cornerstone technology that has enhanced our rapid growth in recent years.

“Developing products with the only technology internationally proven to kill bacteria resistant to silver firmly secures our position as the fastest growing business in the wound care market.”

He added: “We now have an unrivalled antimicrobial platform to tackle the issue of secondary infections faced by clinicians the world over, which will boost our portfolio significantly and bolster our global growth.”

The agreement will also enable Crawford to expand the technology into other wound dressings and formats, including products for bed sores diabetic ulcers.